Abstract HIV-1 envelope glycoprotein gp120 (gp120) is a major virulence protein implicated in the pathogenesis of HIVassociated neurocognitive disorders (HAND). Although gp120 has been suggested to cause synaptic and neuronal injuries by disrupting NMDA receptor (NMDAR) function, the underlying mechanism is unclear. Here, we show that gp120Bal downregulates the phosphorylation of the NMDAR subunit1 NR1 (at Ser896 and Ser897), which is essential for NMDAR function. This effect of gp120Bal is blocked by specific antagonists of both NMDA and AMPA receptors, indicating a critical role of synaptic activation. Furthermore, AMD3100 and maraviroc, antagonists of CCR5 and CXCR4 chemokine receptors, respectively, inhibit the effect of gp120Bal on NR1, suggesting that CXCR4 and CCR5 activation are involved. These findings may provide mechanistic insights into the synaptopathogenesis caused by HIV-1 infection.
Introduction
According to a recent estimate, there are over 35 million people worldwide living with human immunodeficiency virus (HIV) infection (UNAIDS/WHO) (https://www.aids.gov/hiv-aidsbasics/hiv-aids-101/global-statistics/). While HIV-1 is best known for its devastating damage to the immune system that leads to acquired immunodeficiency syndrome (AIDS), the virus also infects the central nervous system (CNS) and cause neurological diseases, especially HIV-associated neurocognitive disorders (HAND). Patients with HAND have cognitive and/or sensorimotor deficits, including mental slowing, memory loss, difficulties in performing complex tasks that require executive functions, and motor disorders (McArthur et al. 2005) . Although highly active antiretroviral therapy (HAART) can suppress viral burden to nearly undetectable levels in cerebrospinal fluid (CSF) and serum, HAND is still observed in as many as half of HIV-1-infected patients (Cysique et al. 2004; Heaton et al. 2010; Heaton et al. 2011) . Thus, it is important to develop rationale-based adjunctive therapy to combat the disorders.
Previous studies showed that HIV-1 infection leads to encephalitis and neuronal apoptosis (Alirezaei et al. 2007; Bachis et al. 2009; Hayward 2004; Mattson et al. 2005) . However, these pathological manifestations and the number of HIV-infected cells do not seem to closely correlate to the HIVassociated cognitive impairments (Glass et al. 1995; Glass et al. 1993) . In contrast, synaptodendritic damage seems to better correlate with the presence and severity of the cognitive deficits (Ellis et al. 2007; Everall et al. 1999; Masliah et al. 1997; Sa et al. 2004) . Synaptodendritic injuries were observed in HIV patients (Sa et al. 2004 ), gp120 transgenic mice (Toggas et al. 1994) , HIV-1 transgenic rats (Rao et al. 2011 ) and in neuron cultures exposed to exogenous gp120 (Iskander et al. 2004; Kim et al. 2011) . HIV-1 gp120, which can modulate various cellular process by activating its chemokine co-receptors CXCR4 or CCR5, was shown to cause synaptodendritic degeneration (Bachis et al. 2009; Kaul et al. 2007 ). In addition, axonal damage may also be associated with HAND, as indicated by the elevated neurofilament protein (NFL) in CSF of patients with HIV dementia (Ellis et al. 2007 ).
The synapses may degenerate in HIV patients, as indicated by the decrease in the number of dendritic spines (Iskander et al. 2004; Masliah et al. 1997; Sa et al. 2004 ). Synapse loss also seems to occur in the gp120 transgenic mice (Toggas et al. 1994) . In addition to synaptic degeneration, HIV-1 proteins may also interfere with synaptic activity (Haughey and Mattson 2002; Kasyanov et al. 2006; Krogh et al. 2014; Nath et al. 1996; Tovar et al. 2013; Xu et al. 2011) . For instance, gp120 was shown to activate N-methyl D-aspartate receptor (NMDAR), and this could induce synaptic damage (Gemignani et al. 2000; Kaul and Lipton 1999; Lipton 1992; Pattarini et al. 1998; Toggas et al. 1996; Viviani et al. 2006; Yang et al. 2013) . Interestingly, T-cell-tropic (T-tropic) gp120 IIIB promoted trafficking and surface clustering of NMDA receptors in membrane microdomains in cultured hippocampal neurons. The gp120 IIIB-regulated NMDAR trafficking was associated with the phosphorylation of the NMDAR subunit NR1 (also known as the GluN1 subunit) at its C-terminal serine 896 (Ser896) and serine 897 (Ser897) (Xu et al. 2011) . It has been shown that phosphorylation at these residues are important posttranslational modifications for NMDAR to be transported from the Golgi complex and thus is a critical step in the process of NMDAR surface expression, which is required for it to become functional at synapses (Scott et al. 2003; Scott et al. 2001) .
HIV-1 viruses isolated from the central nervous system (CNS) are mainly macrophage (M)-tropic (Gonzalez-Perez et al. 2012; Gorry et al. 2001; Peters et al. 2004 ). The M-tropic gp120Bal uses CCR5 (rather than CXCR4 for Ttropic gp120) as a co-receptor. Previous studies indicated that gp120Bal mediates HIV neurotoxicity by a process different from gp120 IIIB (Bachis et al. 2010 ). We were interested in the effects of HIV-1 gp120Bal on NMDA receptors. Intriguingly, we found that, when applied to primary cortical cultures, gp120Bal transiently decreased the level of pSer896 NR1 and pSer897 NR1. These findings indicate that gp120Bal may impair synaptic NMDAR activity by interfering with NR1 trafficking. In addition, our studies showed that gp120Bal-induced down-regulation of pSer896 and pSer897 NR1 is diminished by NMDAR and AMPAR antagonists, as well as the antagonists of CCR5 and CXCR4. Thus, the results suggest that gp120Bal down-regulates the phosphorylated NR1 by a process that depends on synaptic activity and HIV-1 co-receptor activation.
Materials and Methods
Animals All experiments were performed following the protocols that were approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch and were in accord with National Institutes of Health guidelines. Young adult C57BL/6 mice (2-3 months old; 20-25 g body weight) were used. Mice were housed in a constant temperature environment (23 ± 3°C) with standard bedding, free access to food and water, and under a 12/12 h light/dark cycle.
Primary Cortical Cultures Primary cortical cultures were prepared from mouse embryos as described previously (Ru et al. 2012) . Briefly, cortices were dissected from C57BL/ 6 J mouse embryos (E18), and cells were dissociated with trypsin in Hank's balanced salt solution (Invitrogen) with gentle trituration. Cells were plated on poly-D-lysine (30,000-70, 000; Sigma) coated dishes at a density of 1.5 × 10 5 cells/cm 2 in DMEM medium (Invitrogen) containing 10 % FBS (Gibco). Three hours after plating, the medium were replaced with Neurobasal Medium (Invitrogen) supplemented with 2 % B27 (Invitrogen) and 0.5 mM L-glutamine (Invitrogen). One-third of the medium was replenished every 3 days until 12-14 days in vitro (DIV). Only morphologically healthy cultures were used for drug treatments. 
Direct Transcutaneous Intrathecal Injection (i.t.)
For direct transcutaneous intrathecal injection of gp120Bal, a modified version (Li et al. 2013 ) of the original method (Hylden and Wilcox 1980) was used. Mice were initially anaesthetized by inhaling 2.5 % isoflurane, a 30.5-gauge stainless steel needle attached to a 10 μl Hamilton syringe (Hamilton, Reno, NV) was used for i.t. injections. To locate the intervertebral space between L5 and L6, the experimenter used the left index finger to palpate the tip of the sixth lumbar vertebra (L6) and used the right hand to insert the needle into the intervertebral space at a 45°angle. A correct intrathecal placement of the needle tip was judged by a tail twitch. Then, 100 ng (in 5 μl) gp120 protein was injected. Mice injected with vehicle (PBS) were used as controls.
Immunofluorescent Staining Cultured primary cortical cells were fixed with 4 % PFA for 20 min, and blocked in 5 % BSA in 0.1 M PBS with 0.3 % Triton X-100. Fixed cells were incubated overnight (4°C) with chicken anti-MAP2 and rabbit anti-cleaved caspase-3, followed by fluorescently conjugated secondary antibodies (FITC-conjugated goat antichicken lgY and cys3-conjungated goat anti-rabbit IgG) (1:200, Jackson ImmunoResearch Laboratories) at room temperature for 1 h. DAPI was added to visualize cell nuclei when mounting. Images were captured using a confocal microscope (Nikon). Quantitative analysis of captured images was performed using ImageJ. Three to five independent experiments were performed for each treatment.
Western blotting Cortical cultures in 12-well plates (12-14 DIV) were rinsed with PBS and lysed immediately with 100 μl of 2× SDS-PAGE sample buffer (1×: 62.5 mM Tris, pH 6.8, 2 % SDS, 5 % 2-mercaptoethanol, 10 % glycerol, and 0.0025 % bromophenol blue). For in vivo analysis, mice were anesthetized and sacrificed, followed by collecting the L4-L6 lumbar spinal cord segments. The spinal cord tissues from individual animals were homogenized in 500 μl of RIPA lysis buffer (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 0.1 % SDS, 1 % Triton X-100, 0.5 % sodium deoxycholate, 1 mM EDTA, 1 % protease inhibitor mixture (cat# P8340; Sigma-Aldrich) and 1 % phosphatase inhibitor 2/3 (cat # P5726/P0044; Sigma-Aldrich). Protein lysates were prepared and the concentrations were determined using BCA protein assay kit (product 23,227; Pierce) as previously described (Li et al. 2013) . Equal amounts of protein (30 μg/lane) were separated on 10 % Tris-glycine polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore).
Immunoblots were blocked for 2 h in Tris-buffered saline Tween-20 (TBST; 20 mM Tris-HCl, 150 mMNaCl, pH 7.5, 0.05 % Tween-20) containing 5 % non-fat milk. Then, blocked blots were sequentially incubated with primary and secondary antibodies. Protein bands were visualized using the Enhanced Chemiluminescence kit (Pierce), and the intensities of non-saturated bands on Western blots were quantified by densitometry analysis with NIH ImageJ. β-actin was included as a loading control.
Statistical Analysis
Quantitative summary data were expressed as means ± SEM. Statistical analysis was performed with Prism 5 software. We used the one-way analysis of variance (ANOVA) with a Tukey post-hoc test for comparisons among multiple groups, one- The NR1 subunit of NMDAR is an essential subunit that is ubiquitously expressed throughout the brain. Phosphorylation is a key mechanism that regulates the localization and channel function of NMDARs (Scott et al. 2003) . Previous studies indicated that phosphorylation of NR1 at Ser897 and Ser896 contributes to HIV gp120 IIIB-induced NMDAR trafficking and surface expression in cultured hippocampal neurons (Xu et al. 2011) . We wanted to determine in this study if gp120Bal acts similarly in the regulation of NR1 phosphorylation. Interestingly, instead of stimulating NR1 phosphorylation, we observed that exposure of primary cortical culture to 200pM gp120Bal transiently decreases pNR1 (Ser896, Ser897). A significant decrease of pSer896-NR1 was detected between 12 h and 24 h post gp120Bal application (Fig. 1a) , while a decrease in pSer897-NR1 occurred between 6 h and 24 h (Fig. 1b) . The levels of both pSer896-NR1 and pSer897-NR1 returned to baseline after 72 h of gp120Bal treatment ( Fig. 1a and b) . On the other hand, we did not observe significant changes of total NR1 during this period (Fig. 1c) . In addition, when treated with heat-denatured gp120Bal, we did not detect decreases of the phosphorylated NR1 at Ser896, Ser897, or total NR1 (Fig. 1d-f) , indicating that the ability of gp120Bal to down-regulate phosphorylated NR1 requires its bioactivity.
To determine the effects of gp120Bal on pNR1 levels in vivo, we injected gp120Bal intrathecally into adult mice and measured the pSer896 NR1 and pSer897 NR1 levels in the L4-L6 spinal segments at various time points following gp120Bal administration. Our results showed that compared to total NR1, which was unchanged, both pSer896-NR1 and pSer897-NR1 gradually decreased after gp120 injection (Fig. 1g) . The levels of both forms of pNR1 returned to baseline by day 5 (Fig. 1g) . These results indicate that HIV-1 gp120Bal down-regulates phosphorylated NR1 (Ser896 and S897) both in vitro and in vivo.
gp120Bal Treatment Does not Cause Significant Neuron Loss and Dendrites Degeneration
Previous studies showed that gp120-induced CXCR4 activation cause neurotoxicity and lead to neuron death (Hesselgesser et al. 1998; Kaul et al. 2001; Meucci et al. 1998 ). gp120-induced CCR5 activation also causes neuronal apoptosis, but its natural ligands Bregulated-and-normal-Tcell-expressed-and-secreted^(RANTES, CCL5) and MIP-1β prevent the gp120 neurotoxicity (Bachis and Mocchetti 2005; Kaul and Lipton 1999; Kaul et al. 2007; Meucci et al. 1998) . To test whether gp120Bal (200pM) can cause the neural cell apoptosis or dendritic degeneration under our experimental conditions, we stained cleaved-caspase-3 to identify apoptotic cells. We found that gp120 treatment did not significantly increase cleaved caspase-3-positive cells ( Fig. 2a and  b) . This finding was confirmed by Western blot analysis (Fig. 2c) . MAP2 staining, showed that gp120Bal treatment did not alter dendritic morphology (lower panel in Fig. 2a ).
Thus, gp120Bal did not cause apparent neuron apoptosis and dendritic degeneration under our experimental conditions. gp120Bal-Induced Decreases of pSer896-NR1 and pSer897-NR1 Require the Activation of NMDA and AMPA Receptors
Next, we wanted to characterize the mechanism by which gp120Bal induces the decrease of phosphorylated NR1. Because previous studies show that gp120 leads to neuronal degeneration by its excitotoxicity (Haughey and Mattson 2002; Lannuzel et al. 1995; Lipton 1992; Potter et al. 2013; Toggas et al. 1996) , we tested the role of after treated with heat-inactivated gp120Bal. g Gp120Bal decreased phosphorylated NR1 in the spinal cord. Mice were i.t. injected with 100 ng gp120Bal for the indicated times and followed by immunoblotting of the total NR1 and phosphorylated NR1 in the L4-L6 spinal cord, p-NR1(ser896)/NR1 vs. NR1/β-actin, p < 0.001, p-NR1(ser897)/NR1 vs NR1/β-actin, p < 0.01. Quantitative graphs are shown as mean ± SEM (*P < 0.05; **P < 0.01 vs. time 0, n ≥ 3) NMDAR and AMPAR activation. We used D-APV (100 μΜ) to block NMDARs (Morris 1989) , and CNQX (50 μΜ) to block AMPARs (Honore et al. 1988) . We found that although gp120 (200 pM, 12 h) significantly downregulated the phosphorylation of NR1 at Ser896 by 41 % (p < 0.001) (Fig. 3a) , and Ser897 by 40 % (p < 0.01) (Fig. 3b) , pre-treating the cultures with D-APV completely blocked the gp120Bal-induced decreases of pSer896-NR1 (p < 0.05 compared to only gp120Bal treatment; Fig. 3a ) and pSer897-NR1 (p < 0.05 compared to only gp120Bal treatment; Fig. 3b) . Similarly, the AMPAR antagonist CNQX also blocked the effects of gp120Bal on phosphorylated NR1 at Ser896 (Fig. 3d) and Ser897 (Fig. 3e) . However, D-APV and CNQX treatment have no effects on the total amount of NR1 ( Fig. 3c and f) . These data indicated that the activation of both NMDARs and AMPARs are critical for gp120Bal to down-regulate phosphorylated NR1.
Chemokine Receptors CCR5 and CXCR4 Contribute to gp120Bal-Induced Decrease of Phosphorylated NR1
HIV productively infects macrophages and microglia but not neurons, which do not express CD4. Nonetheless, chemokine receptors CXCR4 and CCR5 serve as co-receptors for gp120 and mediate neuronal damage (Bachis et al. 2009; Catani et al. 2000; Kaul et al. 2007 ). While Mtropic HIV-1 strains (e.g. Bal) preferably uses CCR5 as a co-receptor (Alkhatib et al. 1996; Choe et al. 1996; Dragic et al. 1996) , T-tropic strain (e.g. IIIB) use CXCR4 . Dual-tropic strains (e.g. SF2) can use both CCR5 and CXCR4 as co-receptors (Collman et al. 1992; Yi et al. 1999 ). Thus, we performed studies to determine the potential roles of CCR5 and CXCR4 in the gp120Bal-induced decreases of pSer896-NR1 and pSer897-NR1. We employed AMD3100 and maraviroc to inhibit CCR5 and CXCR4, respectively. As we had seen before, . The protein levels of caspase-3 and cleaved-caspase-3 after gp120Bal treatment were also determined by Western blot analysis (c). Scale bar, 50 μm gp120Bal treatment caused significant decreases in the levels of p-Ser896-NR1 and p-Ser897-NR1 after 12 h of treatment. However, pre-treating the cells with either AMD3100 or maraviroc for 30 min blocked the gp120Bal-induced decreases of pSer896-NR1 ( Fig. 4a ; p < 0.05, compared to only gp120Bal treatment) and pSer897-NR1 ( Fig. 4b ; p < 0.05, compared to only gp120Bal treatment)). Neither AMD3100 nor maraviroc had any effect on total NR1 (Fig. 4c) . These results suggest that gp120Bal induces the down-regulation of phosphorylated NR1 via CXCR4 and CCR5.
Discussion
NMDARs play important roles in synaptic transmission and plasticity, as well as memory formation (Bliss and Collingridge 1993; Morris 1989) . Prior studies suggest that NMDARs are activated by gp120, which leads to neuronal damage or death (Dreyer et al. 1990; Geeraerts et al. 2006; Kaul and Lipton 1999; Lipton et al. 1991; Medina et al. 1999 ). The gp120-induced and NMDAR-mediated neuronal injuries likely contribute to HAND such as HIV-1-associated dementia. Despite these significant advancements, we still know little about how gp120 may regulate NMDARs to activate them. Our data described in this paper reveal for the first time a transient effect of gp120Bal on the down-regulation of phosphorylated NR1 (Ser896 and Ser897), both in cortical primary cultures and in the mouse spinal cord. The gp120-induced decrease of NR1phosphorylation is apparently not a consequence of neurotoxicity (Fig. 2) . Since phosphorylation is a key regulatory mechanism for NMDAR trafficking, synaptic targeting, and surface expression (Chen and Roche 2007; Scott et al. 2003) , our findings suggest that gp120Bal may disturb NMDAR function, especially at synapses. The reduced phosphorylation of NR1 at Ser896 and Ser897 may affect the receptor's clustering and decrease its sensitivity to glutamate. However, whether the decreased phosphorylation plays a role in the pathogenesis of HAND or itself is a compensatory response to the HAND is unknown. In this context, it is interesting to note that gp120 IIIB enhances the phosphorylation of the NR1 at both Ser896 and Ser897. It also promotes NMDAR trafficking and surface expression (Xu et al. 2011) . We currently do not know how the different types of gp120 cause apparently opposite effects on NR1 phosphorylation. Our data indicate that activation of NMDARs and AMPARs is essential for gp120Bal to down-regulate pSer896-NR1 and pSer897-NR1. NR1 is an essential subunit of functional NMDARs that can be phosphorylated by a variety of protein kinases. For example, NR1 is phosphorylated by protein kinase C (PKC) on two residues (Ser890 and Ser896) (Tingley et al. 1997) . PKCα phosphorylates Ser896 and PKCγ phosphorylates Ser890 (Sanchez-Perez and Felipo 2005) . cAMP-dependent protein kinase A (PKA) phosphorylates NR1 on Ser897 (Tingley et al. 1997 ). Ser896 and Ser897 are highly phosphorylated in the endoplasmic reticulum and Golgi. The phosphorylation of Ser896 and Ser897 increases the surface expression of NMDARs, suggesting that the phosphorylation of these sites is an important regulatory mechanism for NMDAR intracellular trafficking (Scott et al. 2003; Scott et al. 2001) It is well established that Ca2+ influx following NMDA receptor activation leads to the activation of many kinases, including PKC and PKA. Normally, NMDA receptor activation is primed by AMPA receptor activation, which causes membrane depolarization and relieves of Fig. 4 Chemokine receptors CCR5 and CXCR4 are critical for gp120Bal-induced decreases of pSer986-NR1 and pSer897 NR1. A-B, AMD3100 and maraviroc abolished gp120Bal-induced decrease of pSer986-NR1 (a) and pSer986-NR1 (b). c AMD3100 and maraviroc did not change the amount of total NR1. The primary cortical cultures were pre-treated with the AMD3100 (μM) or maraviroc (50 μM) for 30 min, followed by gp120Bal (200 pM) administration for another 12 h. Cell lysates were analyzed by immunoblotting. Data are expressed as mean ± SEM from at least three independent experiments (*P < 0.05; **P < 0.01; ***P < 0.001, n ≥ 3, vehicle (g) is vehicle of gp120Bal; vehicle (A) is vehicle of AMD3100; vehicle (M) is vehicle of maraviroc)
Mg2+ blockage of the NMDA receptors. Thus, the simplest interpretation of the observed CNQX effect is that it impairs NMDA receptor activation induced by gp120, and consequently the phosphorylation of NR1. Indeed, inhibition of NMDA receptors by APV also blocked the NR1 phosphorylation. Since serine/threonine protein phosphatases such as protein phosphatases 1 (PP1), 2A (PP2A), and 2B (PP2B or calcineurin) regulate the activities of NMDARs (Tong et al. 1995; Wang et al. 1994; Westphal et al. 1999) , the level of the phosphorylated NR1 is presumably determined by the competing action of the kinases and phosphatases.
We observed that the CCR5 antagonist maraviroc blocked the effect of gp120Bal in down-regulating NR1 phosphorylation. This finding indicates that gp120Bal binds to its co-receptor CCR5 to elicit the change. To our surprise, the CXCR4 antagonist AMD3100 was also able to block the gp120Bal-induced decrease of phosphorylated NR1 ( Fig. 4a and b) . Although CXCR4 is the preferable coreceptor for T-tropic gp120, some M-tropic HIV-1 strains can use CXCR4 for entry into monocyte-derived macrophages (Gorry et al. 2001; Gray et al. 2009 ). Thus, it is possible that some gp120Bal may bind to CXCR4 to induce the effect (Igarashi et al. 2003) . Another possibility is that CXCR4 activation by its natural ligand such as CXCL12 induced by gp120Bal contributes to the downregulation of NR1 phosphorylation. CXCL12 has been shown to promote neuronal apoptosis (Bezzi et al. 2001; Hesselgesser et al. 1998; Kaul and Lipton 1999; Zheng et al. 1999) . Because blocking either CCR5 or CXCR4 was able to diminish the effect of gp120Bal, the downregulation of phosphorylated NR1 is likely a consequence of a combined effect of both CCR5 and CXCR4 signaling. For example, following interaction with their specific ligands, activated chemokine receptors could induce higher concentrations of intracellular free calcium (Kaul et al. 2001; Lannuzel et al. 1995; Meucci et al. 1998) , which potentially facilitates action potential firing and neuronal excitation. Chemokine binding can also activate the tyrosine kinase Pyk2 (Davis et al. 1997) , the p38 mitogenactivated protein kinase pathway (Kaul and Lipton 1999) , or calcineurin (Shepherd et al. 2012; Shepherd et al. 2013 ). Therefore, CCR5-and CXCR4-mediated dysregulation of the kinases and/or phosphatases may contribute to the downregulation of phosphorylated NR1.
